RecruitingNot applicableNCT07765823
33
studies recruiting now
as of 7 Sept 2026
335
studies registered in total
as of 7 Sept 2026
12
countries with a recruiting site
as of 7 Sept 2026
14 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT07585890
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
RecruitingPhase 2NCT06916585
Chinese Phase II Trail of AS1501 in Acute-on-chronic Liver Failure (ACLF) Patients
RecruitingNot applicableNCT06831565
Comparison of Blood Products Required Using Two Different ROTEM Cut-offs Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure (ACLF) Patients With Severe Coagulopathy
RecruitingNot applicableNCT07449377
Evaluation of Fibroscan® Performance in Diagnosing Acute Heart Failure in Patients Presenting to the Emergency Department
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 33 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Acute liver failure study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Acute liver failure
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 approved treatment and 2 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Framycetin
Phase 3Acetylcysteine (A-cys)
Phase 2Ornithine
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).